236 related articles for article (PubMed ID: 15299193)
21. Rituximab: an innovative therapy for non-Hodgkin's lymphoma.
Wood AM
Am J Health Syst Pharm; 2001 Feb; 58(3):215-29; quiz 230-2. PubMed ID: 11217177
[TBL] [Abstract][Full Text] [Related]
22. Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma.
Tobinai K
Int J Clin Oncol; 2003 Aug; 8(4):212-23. PubMed ID: 12955576
[TBL] [Abstract][Full Text] [Related]
23. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
Leahy MF; Seymour JF; Hicks RJ; Turner JH
J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
[TBL] [Abstract][Full Text] [Related]
24. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
25. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
26. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
[TBL] [Abstract][Full Text] [Related]
27. [Proteins in haematology].
Clarenbach RE; Mey U
Ther Umsch; 2011 Nov; 68(11):610-7. PubMed ID: 22045523
[TBL] [Abstract][Full Text] [Related]
28. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
29. CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.
Bilić E; Femenić R; Konja J; Simat M; Dubravcić K; Batinić D; Ries S; Rajić L
Coll Antropol; 2010 Mar; 34(1):171-5. PubMed ID: 20432747
[TBL] [Abstract][Full Text] [Related]
30. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
31. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Cvetković RS; Perry CM
BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
[TBL] [Abstract][Full Text] [Related]
32. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Yang H; Rosove MH; Figlin RA
Am J Hematol; 1999 Dec; 62(4):247-50. PubMed ID: 10589082
[TBL] [Abstract][Full Text] [Related]
33. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma.
Gutiérrez A; Rodríguez J; Martínez J; Amezaga R; Ramos R; Galmes B; Bea MD; Ferrer J; Pons J; Sampol A; Morey M; Duran MA; Raurich J; Besalduch J
Leuk Lymphoma; 2006 Jan; 47(1):111-5. PubMed ID: 16321834
[TBL] [Abstract][Full Text] [Related]
34. Rituximab therapy of B-cell neoplasms.
Petryk M; Grossbard ML
Clin Lymphoma; 2000 Dec; 1(3):186-94; discussion 195-6. PubMed ID: 11707828
[TBL] [Abstract][Full Text] [Related]
35. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.
Saito B; Shiozawa E; Yamochi-Onizuka T; Adachi D; Nakamaki T; Tomoyasu S; Omine M; Mitsuya T; Takimoto M; Ota H
Pathol Int; 2004 Sep; 54(9):667-74. PubMed ID: 15363034
[TBL] [Abstract][Full Text] [Related]
37. What is the role of maintenance rituximab in follicular NHL?
Maloney DG
Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281
[TBL] [Abstract][Full Text] [Related]
38. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
39. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
[TBL] [Abstract][Full Text] [Related]
40. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
